Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 9:53 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 625–648 of 691 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Corticosteroid Clear all

Conditions: Uveitis, Intermediate Uveitis, Posterior Uveitis, Panuveitis, Noninfectious Uveitis
Interventions: triamcinolone acetonide (Triesence®); Drug
Lead sponsor: Clearside Biomedical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 3
States / cities: Chicago, Illinois • Omaha, Nebraska • Cleveland, Ohio

Conditions: Non-melanomatous Skin Cancer, Precancerous/Nonmalignant Condition
Interventions: eflornithine, triamcinolone; Drug
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years to 120 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2002
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Asthma
Interventions: BI 671800, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 14
States / cities: Huntington Beach, California • Mission Viejo, California • Stockton, California + 11 more

Conditions: Rhinitis, Allergic, Perennial
Interventions: GW685698X aqueous nasal spray; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 2 Years to 11 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005
U.S. locations: 12
States / cities: Hot Springs, Arkansas • Little Rock, Arkansas • Long Beach, California + 9 more

Conditions: Asthma
Interventions: Beclomethasone Dipropionate/Formoterol Fumarate, Beclomethasone Dipropionate; Drug
Lead sponsor: Chiesi Farmaceutici S.p.A.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,377 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 91
States / cities: Mobile, Alabama • Chandler, Arizona • Encinitas, California + 65 more

Conditions: Lateral Elbow Pain
Interventions: Placebo Injection, Steroid (dexamethasone) Injection; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2010
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Atopic Dermatitis
Interventions: Soak and smear, Dry Smear; Other
Lead sponsor: Yale University; Other
Eligibility: 2 Weeks to 18 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Asthma in Children
Interventions: Tiotropium Bromide; Drug
Lead sponsor: Nemours Children's Clinic; Other
Eligibility: 6 Years to 11 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Asthma
Interventions: Fluticasone/Salmeterol Diskus, Fluticasone Diskus; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 12 Years and older
Enrollment: 459 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 19
States / cities: Tucson, Arizona • San Diego, California • Denver, Colorado + 15 more

Conditions: Hyperglycemia
Interventions: NPH insulin plus Complete Insulin Orders, Complete Insulin Orders; Drug
Lead sponsor: HealthPartners Institute; Other
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Saint Louis Park, Minnesota

Conditions: Kidney Transplantation
Interventions: CP-690,550, tacrolimus; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 20
States / cities: Los Angeles, California • Palo Alto, California • San Diego, California + 12 more

Conditions: Vasculitis, Hypersensitivity, Connective Tissue Diseases, Dermatomyositis, Vasculitis
Interventions: Methylprednisolone, Prednisolone; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 4 Years to 21 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2008
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Asthma
Interventions: Procedure: Investigational Procedures; Other
Lead sponsor: Sanofi; Industry
Eligibility: 6 Years and older
Enrollment: 2,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 63
States / cities: Bessemer, Alabama • Chandler, Arizona • Mesa, Arizona + 49 more

Conditions: Asthma, Rheumatic Disease
Interventions: Drug: Acetaminophen, Drug: Placebo; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Atopic Dermatitis
Interventions: Crisaborole ointment, 2%, Hydrocortisone butyrate cream, 0.1%, Pimecrolimus cream, 1%, Crisaborole Vehicle; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 2 Years and older
Enrollment: 237 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 10
States / cities: Bryant, Arkansas • Encinitas, California • Orange Park, Florida + 7 more

Conditions: COPD
Interventions: Low Dose Corticosteroids, High Dose Corticosteroids; Drug
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 40 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 2
States / cities: New Brunswick, New Jersey • Plainsboro, New Jersey

Conditions: Chronic Hand Dermatitis
Interventions: ASN002, Placebo Oral Tablet; Drug
Lead sponsor: Asana BioSciences; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 17
States / cities: Anniston, Alabama • Los Angeles, California • Hialeah, Florida + 14 more

Conditions: Adrenocortical Carcinoma
Interventions: Pembrolizumab; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2027
U.S. locations: 2
States / cities: Ann Arbor, Michigan • New York, New York

Conditions: Sacroiliac Joint Dysfunction, Sacro-Iliac Spondylosis
Interventions: Dexamethasone, Methylprednisolone, 2% Lidocaine HCl Injection; Drug
Lead sponsor: University of New Mexico; Other
Eligibility: 18 Years to 99 Years
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Post Surgical Ocular Inflammation and Pain
Interventions: KPI-121 1% Ophthalmic Suspension dosed BID, Vehicle of KPI-121 Ophthalmic Suspension dosed BID; Drug
Lead sponsor: Kala Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 520 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 35
States / cities: Chandler, Arizona • Phoenix, Arizona • Artesia, California + 32 more

Conditions: Dermatitis Atopic
Interventions: Amlitelimab, Placebo, Topical corticosteroids, Topical calcineurin inhibitors; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 12 Years and older
Enrollment: 643 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 40
States / cities: Birmingham, Alabama • Fort Smith, Arkansas • Encino, California + 32 more

Conditions: Knee Osteoarthritis
Interventions: Corticosteroid injection; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 40 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: IPF
Interventions: Combined Plasma Exchange (PEX), Rituximab, and Corticosteroids; Drug
Lead sponsor: Michael Donahoe; Other
Eligibility: 18 Years to 80 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Pemphigus Vulgaris (PV)
Interventions: Mycophenolate Mofetil 2 g/Day, Mycophenolate Mofetil (MMF) 3 g/Day, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 5
States / cities: Los Angeles, California • Atlanta, Georgia • Baltimore, Maryland + 2 more

Search by objective public record fields.

Safety Study of Suprachoroidal Triamcinolone Acetonide Via Microneedle to Treat Uveitis

Eflornithine With or Without Triamcinolone in Preventing Nonmelanoma Skin Cancer in Patients With Actinic Keratosis

Bi 671800 in Asthmatic Patients on Inhaled Corticosteroids

A Study Of GW685698X For The Treatment Of Perennial Allergic Rhinitis In Pediatrics

A Study Testing the Superiority of CHF 1535 pMDI 800/24µg Total Daily Dose Compared With CHF 718 pMDI 800µg Total Daily Dose in Adults With Asthma on Medium or High-Dose Inhaled Corticosteroid

Corticosteroid Injection for Common Upper Extremity Problems

A Study Comparing the Efficacy of Two Topical Steroid Application Regimens in Pediatric Patients With Atopic Dermatitis

Tiotropium vs. Inhaled Corticosteroids in Children With Nonatopic Asthma Pilot Study (TioNAAP)

Long-acting Beta Agonist Step Down Study

Hospital Insulin Protocol Aims for Glucose Control in Corticosteroid-induced Hyperglycemia

A 6-Month Study Of CP-690,550 Versus Tacrolimus In Kidney Transplant Patients

Absorption of Corticosteroids in Children With Juvenile Dermatomyositis

A Study Evaluating Disease Characteristics and Outcomes in Participants With Asthma in Routine Clinical Practice

Acetaminophen (Tylenol) for Mood and Memory Changes Associated With Corticosteroid Therapy

A Study of Crisaborole Ointment 2%; Crisaborole Vehicle; TCS and TCI in Subjects Aged ≥ 2 Years, With Mild-moderate AD

Dose of Corticosteroids in COPD

Study to Evaluate ASN002 in Subjects With Moderate To Severe Chronic Hand Eczema

Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical Carcinoma

Particulate vs. Non-Particulate Steroid for Sacroiliac Joint Injection

Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation and Pain

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis on Background Topical Corticosteroids

Do Knee Injections Offer Benefit With Knee Arthritis Pain

Combined PEX, Rituximab and Steroids in Acute Idiopathic Pulmonary Fibrosis Exacerbations

A Study to Assess the Effect of CellCept (Mycophenolate Mofetil) and Reduced Corticosteroids in Patients With Active Pemphigus Vulgaris (PV)